Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and efficacy of out-of-specification ciltacabtagene autoleucel in multiple myeloma
jRCT2053220159Not yet recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Jul 2023
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Countries
- 2
01
Overview
Open-label, single-arm trial of ciltacabtagene autoleucel in multiple myeloma (MM), sponsored by Janssen Pharmaceutical. Primary endpoint: Overall Response Rate (ORR). Planned start Jul 2023; status: not yet recruiting.
02
Drugs
ciltacabtagene autoleucel
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on jRCT2053220159.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2053220159.